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OBSTETRICSClinical experience and follow-up with large
scale single-nucleotide polymorphismebased
noninvasive prenatal aneuploidy testing
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Melissa Stosic, MS; Zachary Demko, PhD; Bernhard Zimmermann, PhD; Matthew Hill, PhD;
Styrmir Sigurjonsson, PhD; Allison Ryan, PhD; Milena Banjevic, PhD; Paula L. Kolacki, MS;
Susan W. Koch, MS; Charles M. Strom, MD, PhD; Matthew Rabinowitz, PhD; Peter Benn, DScOBJECTIVE:We sought to report on laboratory and clinical experience (324 trisomy 21, 82 trisomy 18, 41 trisomy 13, 61 monosomy X;
following 6 months of clinical implementation of a single-nucleotide
polymorphismebased noninvasive prenatal aneuploidy test in high-
and low-risk women.
STUDY DESIGN: All samples received from March through September
2013 and drawn 9 weeks’ gestation were included. Samples that
passed quality control were analyzed for trisomy 21, trisomy 18, tri-
somy 13, and monosomy X. Results were reported as high or low risk
for fetal aneuploidy for each interrogated chromosome. Relationships
between fetal fraction and gestational age and maternal weight were
analyzed. Follow-up on outcome was sought for a subset of high-risk
cases. False-negative results were reported voluntarily by providers.
Positive predictive value (PPV) was calculated from cases with an
available prenatal or postnatal karyotype or clinical evaluation at birth.
RESULTS: Samples were received from 31,030 patients, 30,705 met
study criteria, and 28,739 passed quality-control metrics and received
a report detailing aneuploidy risk. Fetal fraction correlated positively
with gestational age, and negatively with maternal weight. In all, 507
patients received a high-risk result for any of the 4 tested conditionsFrom the Division of Fetal Medicine, Department of Obstetrics and Gynecolog
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in follow-up analysis, 356 were high risk, and outcome information
revealed 184 (51.7%) true positives, 38 (10.7%) false positives, 19
(5.3%) with ultrasound findings suggestive of aneuploidy, 36 (10.1%)
spontaneous abortions without karyotype confirmation, 22 (6.2%)
terminations without karyotype confirmation, and 57 (16.0%) lost to
follow-up. This yielded an 82.9% PPV for all aneuploidies, and a
90.9% PPV for trisomy 21. The overall PPV for women aged35 years
was similar to the PPV for women aged<35 years. Two patients were
reported as false negatives.
CONCLUSION: The data from this large-scale report on clinical
application of a commercially available noninvasive prenatal test
suggest that the clinical performance of this single-nucleotide
polymorphismebased noninvasive prenatal test in a mixed high-
and low-risk population is consistent with performance in validation
studies.
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TABLE 1
Demographics of commercial cases
Demographic
Whole cohort,
n[ 31,030
Follow-up cohort,
n[ 17,885
Maternal age, ya
Mean 33.3  6.0 33.7  6.1
Median 35.0 35.0
Range 14.0e60.0 14.0e52.0
Gestational age, wk
Mean 14.0  4.4 14.5  4.7
Median 12.6 13.0
Range 3.1e40.9 9.0e40.9b
Maternal weight, lbc
Mean 158.4  39.2 157.2  37.9
Median 149.0 148.0
Range 83.0e425.0 83.0e385.0
Fetal fraction, %
Mean 10.2  4.5 10.8  4.4
Median 9.6 10.1
Range 0.6e50.0 3.7e50.0b
a At estimated date of delivery; b As the follow-up cohort does not include any out-of-specification cases, or any cases that
failed to receive a noninvasive prenatal testing result, minimum gestational age and fetal fraction are higher than in the
whole cohortehowever, mean values and SD are equivalent between the 2 cohorts; c Analysis of maternal weight was
limited to centers and laboratories that provided this information, and samples originating from United States to avoid
inconsistent weight units.
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current screening methods. Opinion
statements by national and international
professional societies support the clinical
use of NIPT in pregnant women, with
most recommending use restricted to
women at high risk for fetal aneu-
ploidy.15-17
Two approaches to NIPT have been
developed and commercialized. In the
ﬁrst approach, fetal chromosome copy
number is determined by comparing
the number of sequence reads from
the chromosome(s) of interest to those
from reference chromosomes.7,8,11-13,18-22
The second approach entails tar-
geted ampliﬁcation and sequencing
of single-nucleotide polymorphisms
(SNPs).2-5,23,24 This approach requires a
sophisticated informatics-based method
to compute aneuploidy risk through
SNP distribution. Validation of the
SNP-based NIPT method at 11-13
weeks’ gestation was recently reported,
demonstrating high sensitivity and
speciﬁcity for detection of trisomy 21,
trisomy 18, trisomy 13, Turner syn-
drome (monosomy X), and triploidy.2,3
Despite hundreds of thousands of
tests already having been performed
worldwide, there are few large-scale re-
ports describing performance of NIPT in
actual clinical settings,22,25 with most
studies reporting on <1000 total pa-
tients.26-29 Here, laboratory and clinical
experience of >31,000 women who
received prenatal screening with a SNP-
based NIPT is reported.
MATERIALS AND METHODS
This is a retrospective analysis of pro-
spectively collected data on 31,030
cases received for commercial testing
from March through September 2013.
This study received a notiﬁcation of
exempt determination from an insti-
tutional review board (Albert Einstein
College of Medicine Institutional
Review Board: no. 2014-3307). Samples
were classiﬁed as out of speciﬁcation
and excluded in cases of gestational
age <9 weeks, multiple gestation,
donor egg pregnancy, surrogate carrier,
missing patient information, sample
received >6 days after collection,
insufﬁcient blood volume (<13 mL),527.e2 American Journal of Obstetrics& Gynecolwrong collection tube used, or if the
sample was damaged.
Analysis was performed for all sam-
ples on chromosomes 13, 18, 21, X,
and Y, and included detection of trisomy
21, trisomy 18, trisomy 13, and mono-
somy X. All samples were processed
and analyzed at Natera Inc’s Clinical
Laboratory Improvement Act (CLIA)-
certiﬁed and College of American
Pathologists (CAP)-accredited labora-
tory (San Carlos, CA). Laboratory
testing was performed as previously
described using validated methodologies
for cfDNA isolation, polymerase chain
reaction ampliﬁcation targeting 19,488
SNPs, high-throughput sequencing,
and analysis with the next-generation
aneuploidy test using SNPs (NATUS)
algorithm.2-5 Samples were subject to a
stringent set of quality-control metrics.
A second blood draw (redraw) was
requested if total input cfDNA, fetalogy NOVEMBER 2014cfDNA fraction, or signal-to-noise ratio
did not meet quality metrics, or for poor
ﬁt of the data to the model. In cases of
large regions (>25%) of loss of hetero-
zygosity or suspected maternal or fetal
mosaicism, redraw was not requested.
Reports included a risk score for the 4
aneuploidies; when requested, reports
included fetal sex. Risk scores were
calculated by combining the maximum
likelihood estimate generated by the
NATUS algorithm with maternal and
gestational age prior risks. All samples
with a risk score 1/100 were reported
as high risk for fetal aneuploidy and
samples with risk scores <1/100 were
considered low risk. For the purposes of
this study, the high-risk results were
further divided into a maximum-risk
score of 99/100 or an intermediate-risk
score of 1/100 and <99/100. The
presence of >2 fetal haplotypes (indic-
ative of either triploidy or multiple
FIGURE 1
Study flow chart
OOS: see “Materials and Methods” section.
OOS, out-of-specification; QC, quality control.
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FIGURE 2
Father sample and clinical
laboratory experience reduces
redraw rate
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Decrease in redraw rates overall and for patients
including a paternal sample during the reporting
period (March through September 2013) for
samples 10 weeks of gestation.
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ajog.org Obstetrics Researchgestation) was reported only when the
conﬁdence was >99.9%. Additional sex
chromosome aneuploidies (XXX, XXY,
and XYY) were reported from June 2013.
The following patient characteristics
were requested for each sample:
maternal date of birth, maternal weight,
gestational age, and whether a paternal
sample was included.
Patients with available International
Classiﬁcation of Diseases, Ninth Revision
(ICD-9) codes (Appendix; Supplementary
Table 1) were categorized into 3 sub-
cohorts: (1) “low risk” if aged <35 years
and no aneuploidy-related high-risk
codes; (2) “at risk” for fetal aneuploidy
based solely onmaternal age35 years; or
(3) “high risk” for fetal aneuploidy by
ICD-9 code, regardless of maternal age.
High-risk indications included positive
screening tests, ultrasound anomalies, and
relevant family history. Patients without
reported ICD-9 codes were categorized by
maternal age as low risk (<35 years) or
high risk (35 years).
Follow-up information on high-risk
results was obtained by telephone and
recorded in an internal database. Clinical
follow-up was completed on June 14,
2014, at which time all pregnancies were
completed. Two partner laboratoriesaccounting for 38.1% of the total 31,030
cases were responsible for their own
follow-up efforts and were excluded
from outcome calculations. Providers
were encouraged to share information
about false-negative (FN) results. Sam-
ples were categorized as follows: (1)
“true positive” (TP) included high-risk
samples that were conﬁrmed by prena-
tal or postnatal diagnostic testing, or
based on clinical evaluation at birth; (2)
“FP” included high-risk samples that
were shown to be euploid by follow-up
testing or based on clinical evaluation
at birth; (3) “suggestive” included sam-
ples where prenatal ultrasound detected
at least 1 structural anomaly and 1 soft
sonographic marker consistent with
NIPT ﬁndings, but karyotype conﬁr-
mationwas not obtained; (4) “pregnancy
loss” where the patient experienced
spontaneous abortion and karyotype
conﬁrmation was not obtained; (5)
“termination” where the patient elected
to end the pregnancy without karyotype
conﬁrmation; (6) “no follow-up”
included samples where informationwas
unavailable; and (7) “FN” included
NIPT low-risk samples that were re-
ported as aneuploid by the provider.
When placental and fetal karyotypes
were both available and determined to be
discordant, NIPT ﬁndings were consid-
ered TP if they matched the fetal kar-
yotype, and FP if they did not match the
fetal karyotype. Pregnancies were
considered mosaic when chromosome
analysis revealed either placental or fetal
mosaicism or there was discordance be-
tween placental and fetal karyotypes.
Patient and sample characteristics
were expressed as means, SD, medians,
and ranges. Linear regression analysis
was used to determine the relationship
between fetal fraction and gestational
age, between fetal fraction and maternal
weight, and between fetal/maternal
cfDNA and maternal weight; a recip-
rocal model was used when determining
the relationship between fetal fraction
and gestational age or maternal weight.
For comparison of euploid and aneu-
ploid calls, fetal fractions were expressed
as multiples of the median (MoM)
relative to low-risk calls weighted
by week of gestation, and signiﬁcanceNOVEMBER 2014 Ameridetermined using aMann-Whitney rank
sum test. The 2 FN results were included
in the appropriate aneuploid category,
and FP calls were excluded from aneu-
ploidy fetal fraction analyses. The
beneﬁt of a paternal sample on redraw
rates and differences in aneuploidy
incidence between the a priori risk
groups were determined using a c2 test.
The Kruskal-Wallis 1-way analysis of
variance on ranks test was used to eval-
uate maternal age and gestational age
differences for the different risk groups.
Positive predictive value (PPV) ([TP]/
[TPþ FP]) was calculated for cases with
known cytogenetic analyses. SigmaPlot
12.5 (Systat Software, San Jose, CA) was
used for all statistical analyses. P < .05
was considered statistically signiﬁcant.
RESULTS
Patients and samples
Patient and sample characteristics for the
31,030 cases received during the study
period are detailed in Table 1. Mean
maternal age was 33.3 years, with 51.4%
(15,952) aged35 years at the estimated
date of delivery. Mean gestational age
was 14.0 weeks, with 64.5% (20,001) of
samples drawn in ﬁrst trimester and
33.8% (10,479) in the second trimester.
Figure 1 depicts the study ﬂow
chart. Samples from 325 (1.0%) patients
were excluded as being outside of thecan Journal of Obstetrics& Gynecology 527.e3
FIGURE 3
Effect of gestational age and maternal weight on fetal fraction
Box plots depicting effects of A, gestational age and B, maternal weight on fetal fraction. Boxes
indicate 75th (upper) and 25th (lower) quartiles, solid black line within box indicates median, capped
whiskers indicate 90th (upper) and 10th (lower) percentiles, number in each grouping is indicated
above 90th percentile whisker.
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Table 2) and 1966 samples failed quality-
controlmetrics (Supplementary Table 3),
mostly due to low fetal fraction, leaving
28,739 cases with NIPT results.
In 21,678 cases from clinics linking
patient samples to a single case identiﬁ-
cation, 386 ﬁrst draws did not meet re-
quirements, thereby allowing analysis of
redraw rates in 21,292 cases. A redraw
was requested from 95.4% (1572/1648)
of cases without a ﬁrst draw result,
56.5% (888/1572) submitted a redraw,
and 64.3% (571/888) of redraws were
reported; 12 (2.1%) resolved redraws
received a high-risk call. Redraw rates
declined steadily over the reporting
period (Figure 2); the most recent ﬁrst
sample redraw rates were 9.4% at 9
weeks’, and 5.4% at 10 weeks’ gesta-
tion. Around 30% of patients given the
opportunity to submit a paternal sample
chose to do so, and inclusion of a
paternal sample was associated with a
lower redraw rate, with a similar decline
over the study period (Figure 2). This
effect was more pronounced in women
weighing >200 lb, where inclusion of a
paternal sample reduced the redraw rate
from 27.5% to 16.1% (P < .001). The
average turn-around time was 9.2 cal-
endar days (95% conﬁdence interval
[CI], 9.16e9.23 calendar days), but sig-
niﬁcant improvements over the study
period led to an average turn-around
time in the last month of 6.7 calendar
days (95% CI, 6.68e6.76 calendar days).
Fetal fractions
The average fetal fraction was 10.2%
(Table 1). Regression analysis, using
the reciprocal of the independent vari-
able (gestational age or maternal
weight), revealed a positive correlation
between fetal fraction and gestational
age (r2 ¼ 0.05, P < .001) (Figure 3, A),
and a negative association between fetal
fraction and maternal weight (r2 ¼
0.16, P < .001) (Figure 3, B). Further-
more, with increasing maternal weight,
there was an increase in maternal
cfDNA (P < .001) and a decrease in
fetal cfDNA (P < .001) (Figure 4). Fetal
fractions when stratiﬁed by aneuploidy
were decreased for trisomy 13 (0.759
MoM, P < .001), trisomy 18 (0.919527.e4 American Journal of Obstetrics& GynecolMoM, P ¼ .012), and monosomy
X (0.835 MoM, P < .001), and in-
creased for trisomy 21 (1.048 MoM,
P ¼ .018) samples.
NIPT results
The combined rate of high-risk calls for
all 4 indications was 1.77% (508/
28,739); including 324 trisomy 21, 82
trisomy 18, 41 trisomy 13, and 61
monosomy X (Table 2). One sample was
not assigned a risk score for chromo-
some 21 due to a maternal chromosome
21 partial duplication but was accurately
identiﬁed as fetal trisomy 21 by theogy NOVEMBER 2014laboratory. Of 20,384 samples evaluated
for additional sex chromosome aneu-
ploidies, other than monosomy X, there
were 14 (0.07%) identiﬁed: 6 XXX, 6
XXY, and 2 XYY. Fetal sex was reported
in 24,522 cases. There were no reports of
gender discordance from women
receiving low-risk reports. For women
receiving high-risk reports, conﬁrma-
tion of fetal sex was available for 109
cases, of which 108 (99.1%) were cor-
rect; the single discordant case was re-
ported as high-risk for monosomy X
(Supplementary Figure) but cytogenetic
testing revealed a 46, XY fetus. Although
FIGURE 4
Increasing maternal weight increases maternal cfDNA and decreases
fetal cfDNA
Box plots depicting absolute levels of A, maternal and B, fetal cell-free DNA in maternal circulation as
a function of maternal weight. Boxes indicate 75th (upper) and 25th (lower) quartiles, solid line within
box indicates median, dashed line within box indicates mean, capped whiskers indicate 90th (upper)
and 10th (lower) percentiles, diamonds indicate 95th (upper) and 5th (lower) percentiles.
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were excluded, the NATUS algorithm
identiﬁed 127 (0.4%) samples as having
>2 fetal haplotypes, indicative of either
unreported twins, vanishing twin, or
triploidy.
ICD-9 codes were associated with
19.0% (5468/28,739) of women: 16.6%
were low-risk, 44.1% were high-risk
based only on advanced maternal age
(35 years), and 39.3% had high-risk
codes. As expected, the incidence of
aneuploidy calls was smallest in the low-
risk group (0.7%), followed by advanced
maternal age women (1.6%), and largest
in the high-risk group (3.4%) (Table 3).
Results for the 23,271 samples with-
out ICD-9 codes showed a similar dif-
ference in aneuploidy calls between
women aged <35 years (1.0%, 117/
11,629) and those aged35 years (2.4%,
274/11,642).
Follow-up of high-risk calls
From 17,885 cases in the follow-up
cohort, outcome information was
sought for the 356 high-risk calls; 152
high-risk calls from the whole cohort
described above were not contained
within the follow-up cohort.
Information regarding invasive testing
uptake was available for 251/356
(70.5%) cases that received a high-risk
result: 39.0% (139) elected invasive
testing and 31.5% (112) declined inva-
sive tests, and of the remaining 105
(29.5%), 39 had a spontaneous demise
or elective termination. Within the
356 high-risk calls, there were in total
58 reported spontaneous abortions,
including 16 cases categorized as TP, 2
FP, 4 with ultrasound ﬁndings suggestive
of aneuploidy, and 36 with unconﬁrmed
outcomes. There were 57 reported elec-
tive terminations, including 30 cases
categorized as TP, 5 with ultrasound
ﬁndings suggestive of aneuploidy, and
22 elective terminations with uncon-
ﬁrmed outcomes.
At the conclusion of clinical follow-
up, 62.4% (222/356) of high-risk calls
had karyotype information or at-birth
conﬁrmation: 184 conﬁrmed affected
pregnancies (TP) and 38 unaffected
pregnancies (FP) (Table 4). Eight cases
showed placental or fetal mosaicism:5 fetal mosaics (TP) were conﬁrmed by
amniocentesis (2 trisomy 21, 2 trisomy
18, 1 monosomy X), and 3 cases were
considered FP because of conﬁned
placental mosaicism (CPM). Two CPM
cases were high risk for trisomy 13 and
were identiﬁed as mosaics by chorionic
villus sampling (CVS), one was deter-
mined to be euploid by amniocentesis,
and the other did not have a follow-upNOVEMBER 2014 Ameriamniocentesis but ultrasound at 20
weeks was read as normal. In the third
CPM case, at-birth testing revealed a
100% trisomy 18 placenta and a euploid
child. Two FN results (both trisomy 21)
were reported to the laboratory
following amniocentesis due to other
indications.
For the sex chromosome aneu-
ploidies XXX, XXY, and XYY, 7 of thecan Journal of Obstetrics& Gynecology 527.e5
TABLE 2
Number of fetal aneuploidy high-risk calls in reported commercial cases
All cases, N[ 28,739a Trisomy 21 Trisomy 18 Trisomy 13 Monosomy X
Risk 99/100 298b 78b 26 53
1/100  Risk <99/100 25 4 15 8
Total 324b,c 82b 41 61
Prevalence, 1 in: 88 349 697 467
a Total number of cases with reported result at9 wk of gestation; b Trisomy 21 and trisomy 18 totals include a single case of
double-aneuploidy; c Includes 1 case with a detected partial maternal chromosome 21 duplication, the fetus was determined
to be high risk for trisomy 21 but the algorithm did not calculate a risk score.
Dar. Clinical performance of SNP-based NIPT. Am J Obstet Gynecol 2014.
Research Obstetrics ajog.org14 high-risk calls were within the
follow-up cohort. Clinical follow-up
revealed 4 cases with known out-
comes: 2 TP (1 XXX, 1 XXY) and 2 FP
(both XXX).
Based on the cases with cytoge-
netic conﬁrmation, women with an
intermediate-risk score were more
likely to have a FP result (19/24, 79.2%)
than women with a maximum-risk
score (19/198, 9.6%, P < .001). For
the 36 cases that experienced sponta-
neous abortion and did not obtain
karyotype conﬁrmation, 33 (91.7%)
had a maximum-risk score. All 22
patients who elected to terminate the
pregnancy without conﬁrmation had a
maximal-risk score.
Positive predictive value
Based only on cases with cytogenetic
diagnosis (Table 4), the PPV was
90.9% for trisomy 21 and 82.9% for all 4
cytogenetic abnormalities combined
(Table 5). A theoretical PPV was also
calculated under the 2 boundary condi-
tions that all unconﬁrmed high-risk
cases were either FP or TP (Table 5).
This provided a range for the PPV of
60-94% for trisomy 21 and 52-89% for
all abnormalities combined.
Among women without ICD-9-coded
indications, 63 women aged <35 years
received high-risk calls, of which 39
(60.9%) had diagnostic testing and
34 were TP, a PPV of 87.2% (95% CI,
72.6e95.7%). Of 176 women 35 years
with high-risk calls, 105 (59.7%) had
conﬁrmatory karyotyping and 87wereTP,
a PPVof 82.9% (95% CI, 74.3e89.5%).
COMMENT
This report of initial clinical experience
with this SNP-based NIPT in >31,000
pregnancies demonstrates that perfor-
mance in clinical settings is consistent
with validation studies.2-5 Using only
cases conﬁrmed through chromosome
analysis or clinical evaluation at birth,
the PPV in this mixed low- and high-risk
population is 90.9% for trisomy 21 and
82.9% for all 4 aneuploidies, which is far
better than current screening methods.
Even under the highly conservative
assumption that all unconﬁrmed high-
risk cases are incorrect, this test still527.e6 American Journal of Obstetrics& Gynecoloffers improved clinical performance
over traditional screening.
The main advantage of this study is
the robust information it provides on
clinical application of NIPT, which can
contribute to, and improve, both test
performance and counseling of patients.
Fetal fraction, the main variable that af-
fects redraw rates, is positively correlated
with gestational age and negatively
correlated with maternal weight,
agreeing with previous studies.30-33
There are 2 main clinical implications
from these ﬁndings. First, adequate
dating will lower the need for redraw,
particularly at early gestational ages.
Second, inclusion of a paternal blood
sample signiﬁcantly lowers redraw rates
and should be offered to patients,
particularly those >200 lb. Importantly,
cases with extremely low fetal fraction,
which typically do not resolve with
redraw, may have an increased risk for
fetal aneuploidy.2 This is likely particu-
larly important for maternal triploidy,
which is associated with smaller pla-
centas and lower fetal fractions,2,5 and
trisomy 13 and trisomy 18 pregnancies.
In addition to determining the most
likely ploidy state of a fetus, the NATUS
algorithm also generates a chromosome-
speciﬁc risk score, which is a measure of
the probability of nonmosaic fetal
aneuploidy. As expected, data showed
that maximum-risk results are more
likely to be TP than intermediate-risk
results. Although a high-risk score ap-
pears to bemore indicative of a TP result,
individual numerical values should be
interpreted cautiously. Regardless of the
risk score, conﬁrmatory studies must be
offered to all womenwith positive resultsogy NOVEMBER 2014without exception. This is particularly
important in light of the ﬁnding here
that 6.2% of women with high-risk re-
sults chose to terminate the pregnancy
without invasive test conﬁrmation.
Although referred to as fetal cfDNA,
the primary source of cfDNA is placental
trophoblast cells.34 CPM, estimated to be
present in 1-2% of 10- to 12-week ges-
tations,35,36 impacts all NIPTs. Valida-
tion studies have typically excluded
samples with fetal mosaicism or CPM.
Yet, it is clear that when NIPT is per-
formed in a clinical setting, the effect of
mosaicism cannot be ignored, and its
impact on FP and FN results should be
addressed. In this cohort, 8/222 (3.6%)
high-risk calls showed evidence of
mosaicism. Two cases with CVS results
that supported NIPT ﬁndings were later
categorized as FPs because of CPM.
Further, since most FPs in this cohort
were determined by amniocentesis or at-
birth testing without placental genetic
analysis, there may be additional, unde-
tected CPM cases within the FPs. From a
retrospective analysis of CVS, Grati
et al37 estimated that the FP rate would
be 0.08% for the 4 common aneu-
ploidies. Our ﬁndings, combined with
the known incidence of CPM-related
FPs and FNs, further reinforce the need
for adequate pretest counseling, as rec-
ommended by American Congress of
Obstetrics and Gynecology (ACOG).17
Patients undergoing CVS following
high-risk results with NIPT should be
counseled that mosaic conditions can
occur and later amniocentesis may be
required.
An unexpected ﬁnding in this study
was that the PPV for women aged <35
TABLE 3
Aneuploidy calls in different a priori risk groups
Variable
Cases with ICD-9 codes, n[ 5468 Cases without codes, n[ 23,271
Low risk, age <35 y
(n[ 909)
AMA only, age ‡35 y
(n[ 2411)
High risk, all ages
(n[ 2148)
Low risk, age <35 y
(n[ 11,629)
High risk, age ‡35 y
(n[ 11,642)
Maternal age, ya
Median (range)
28.2  4.4 37.8  2.4 31.3  5.8 28.4  4.5 37.9  2.5
29.0 (15.0e34.0) 37.0 (35.0e48.0) 32.0 (15.0e47.0) 29.0 (14.0e34.0) 37.0 (35.0e52.0)
Gestational age, wka
Median (range)
14.1  4.4 13.3  3.5 15.8  5.0 14.7  4.9 13.4  3.9
12.4 (9.0e33.3) 12.4 (9.0e38.1) 14.4 (9.0e37.0) 13.0 (9.0e38.0) 12.1 (9.0e40.9)
Euploid 903 2368 2073 11,457 11,293
Trisomy 21 2 27b 50 57 188
Trisomy 18 1 5b 13 21 42
Trisomy 13 1 5 3 11 21
Monosomy X 2 2 6 28 23
Total aneuploids 6 38 72 117 274
Monosomy X prevalence, % 0.22 0.08 0.28 0.24 0.20
Trisomy prevalence, % 0.44 1.49 3.07 0.77 2.16
Overall prevalence, % 0.66c 1.58c 3.35c 1.01d 2.35d
Women with ICD-9 codes were sorted into 3 risk populations based on ICD-9 codes and maternal age: low-risk women aged<35 y, women of AMA (aged35 y) with no other high-risk codes, and high-risk women of any age. Women without ICD-9 codes were
sorted into 2 risk populations based on maternal age: low-risk women aged <35 y and high-risk women of AMA.
AMA, advanced maternal age; ICD-9, International Classification of Diseases, Ninth Revision.
a Mean  SD, there was a significant difference between risk groups (P < .001) for both maternal age and gestational age, as determined by the Kruskal-Wallis 1-way analysis of variance on ranks test; b Trisomy 21 and trisomy 18 totals include single case of
double-aneuploidy; c Significant difference in aneuploidy call rate among 3 groups with ICD-9 codes (P< .001), as determined by c2 test; d Significant difference in aneuploidy call rate between 2 groups without ICD-9 codes (P< .001), as determined by c2 test.
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TABLE 4
Clinical follow-up findings
N[ 17,885a Trisomy 21 Trisomy 18 Trisomy 13 Monosomy X Total
High-risk calls 233b 55b 30 38 356
Confirmed outcomes
True positive 140c 27 8 9 184
False positive 14d 2e 13f,g 9 38
Unconfirmed outcomes
Suggestiveh 8 9 0 2 19
Pregnancy lossi 18 6 3 9 36
Terminationj 14 3 0 5 22
No follow-upk 39 8 6l 4 57
Low-risk calls
Confirmed outcomes
False negative 2 0 0 0 2
a Total number of cases with reported result at 9 wk of gestation from participating centers; b Trisomy 21 and trisomy 18
totals include single double-aneuploidy case; c Includes 13 cases reported as trisomy 21 based on at-birth clinical evalu-
ation; d Includes 3 cases reported as normal based on at-birth clinical evaluation; e Includes 1 confined placental mosaicism
case; f Includes 2 confined placental mosaicism cases (1 confirmed and 1 unconfirmed); g Includes 1 case reported as
normal based on at-birth clinical evaluation; h Patients declined invasive testing but ultrasound findings were consistent with
noninvasive prenatal testing findings (see “Materials and Methods” section); i Patients experienced spontaneous abortion
and did not obtain karyotype confirmation; j Patients chose to terminate pregnancy without diagnostic testing; k Follow-up
information was not available; l One sample tested as high-risk (1/7.6) for fetal aneuploidy, analysis of second sample
indicated that patient was at low-risk, follow-up information was not available.
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Research Obstetrics ajog.orgyears (87%) was similar to that of
women aged35 years (83%). This does
not appear to be attributable to a bias in
the referral of cases for karyotyping.
Some women aged <35 years may have
chosen NIPT because of ultrasound
ﬁndings or positive results with tradi-
tional serum screening. However, the
lower aneuploidy call incidence of 1.0%TABLE 5
Positive predictive values
Variable Trisomy 21
Cytogenetically confirmed cases
TP/(TP þ FP) (PPV) 140/154 (90.9%)
All unconfirmed cases considered as FPs (lower
TP/(TP þ FP) (PPV) 140/233 (60.1%)
All unconfirmed cases considered as TPs (uppe
TP/(TP þ FP) (PPV) 219/233 (94.0%)
PPV calculated as (TP)/(TPþ FP). Data are presented for just tho
were FPs (lower bound) and the opposite condition that all unco
FP, false positive; PPV, positive predictive value; TP, true positiv
Dar. Clinical performance of SNP-based NIPT. Am J Obste
527.e8 American Journal of Obstetrics& Gynecolin women aged <35 years, vs 2.4% in
women aged 35 years (Table 3), sup-
ports that these 2 groups of women do
differ substantially with respect to
aneuploidy incidence. The PPV was ex-
pected to be lower in low-risk women
because the number of affected preg-
nancies would be lower but the number
of FPs was predicted to be a constantTrisomy 18 Trisomy 13
27/29 (93.1%) 8/21 (38.1%)
bound)
27/55 (49.1%) 8/30 (26.7%)
r bound)
53/55 (96.4%) 17/30 (56.7%)
se cases where there was cytogenetic or clinical confirmation of resul
nfirmed results were TP (upper bound).
e.
t Gynecol 2014.
ogy NOVEMBER 2014proportion.38 The similar PPVs deter-
mined in both maternal age groups may
indicate that FPs, like affected pregnan-
cies, are also proportionately more
common in older women; perhaps
arising from trisomic conceptions that
are rescued but express CPM. More data
are needed to conﬁrm this observation.
Based on the current opinion state-
ment from ACOG, NIPT is appropriate
for use in high-risk patients.17 Never-
theless, the ability to detect aneuploidy
with cfDNA depends on assay precision
and fetal fraction, not on disease preva-
lence. Reported PPV in studies per-
formed on mixed high- and low-risk
populations, as well as the current study,
far exceed current screening methodolo-
gies. Consistent with this, recent guide-
lines published by the American College
of Medical Genetics and Genomics
(ACMG) do not distinguish between
high and low risk. Therefore, the transi-
tion of NIPT into a universal, ﬁrst-line,
aneuploidy screen should depend on
the availability and affordability of NIPT,
and not concerns about performance.
In this cohort of women who were
thought to have singleton pregnancies at
the time of NIPT, 127 cases were identi-
ﬁed as having >2 fetal haplotypes sug-
gesting either triploidy or a previously
undetected multifetal pregnancy or van-
ishing twin. The SNP-based NIPTmeth-
odology provided the opportunity to
identify these cases, pursue further diag-
nostic avenues, and avoid FPs that can
arise using alternative methodologies.22Monosomy X Total
9/18 (50.0%) 184/222 (82.9%)
9/38 (23.7%) 184/356 (51.7%)
29/38 (76.3%) 318/356 (89.3%)
t; based on the extreme condition that all unconfirmed cases
ajog.org Obstetrics ResearchThe main limitation of this study is
the incomplete follow-up data, partic-
ularly on low-risk patients, precluding
precise calculation of sensitivity and
speciﬁcity. While follow-up was not
conducted on low-risk patients, given
the clinical signiﬁcance of a FN report,
and based on our laboratory experi-
ence, it is likely that FNs would be
voluntarily reported; there were 2
voluntarily reported FNs. However, the
lack of comprehensive follow-up on all
low-risk patients precluded determi-
nation of the negative predictive value.
Nevertheless, it is important to note
that strong performance characteristics
were in keeping with prior validation
studies,2,3,24 even with the inclusion of
mosaic samples. Follow-up of normal
results remains an issue for all labora-
tories that wish to track results for
quality assurance, and we support the
ACMG recommendation for a national
registry.16
In conclusion, this is a large-scale
report of clinical utilization of NIPT.
Analysis of >31,000 samples from both
low- and high-risk women supported
that test performance of this NIPT
method in a clinical setting mirrors the
robust performance reported in valida-
tion studies.
Clinical performance of SNP-based
NIPT in a mixed high- and low-risk
population is consistent with perfor-
mance in validation studies. Similar
PPVs were found in women aged <35
years and aged 35 years. The strength
of the study is the robust information it
provides on clinical application of NIPT.
The primary limitation is the incomplete
follow-up data, particularly on low-risk
patients, precluding precise calculation
of sensitivity and speciﬁcity.
This study supports the use of NIPT
as a ﬁrst-line screening test for aneu-
ploidy in all patients. Furthermore, it
highlights the importance of, as well as
provides data that can improve, coun-
seling of patients. Finally, the results of
this study raise the questions of how
many FP results may be explained by
CPM and how best to manage clinical
care and diagnostic conﬁrmation of
high-risk NIPT results in light of po-
tential CPM. The extent to which CPMmay underlie NIPT FP results requires
further investigation. -
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ajog.org Obstetrics ResearchAPPENDIXSUPPLEMENTARY FIGURE
45,X/46,XY mosaicism may explain the single discordant fetal sex result
Single-nucleotide polymorphism (SNP) data for single discordant fetal sex case are consistent with monosomy X fetus. Representative A, X-chromosome
and B, Y-chromosome SNP plots from female (XX), male (XY), and monosomy X (45,X) fetuses are shown using samples with fetal fractions of around
10% (I) and 20% (II). X-axis of each SNP plot represents the position along the chromosome, and y-axis indicates allele ratio. A, Fetal SNP data are
colored based on maternal genotype, with alleles arbitrarily labeled as A or B: where AA is blue, AB is green, and BB is red. When the maternal genotype is
homozygous at a specific SNP location (red or blue dots), the presence of single X-chromosome (45,X fetus or XY fetus) can easily be distinguished from 2
X-chromosomes (XX fetus); 45,X fetus with single paternal X-chromosome has a different SNP profile to that shown, but is easily distinguished by the
absence of maternal X-chromosome-derived SNPs in the fetus. B, Males are determined by the presence of Y-chromosome SNPs; as fetal fraction
increases, Y-chromosome SNPs migrate further away from X-axis, but Y-chromosome SNPs remain detectable down to at least 4% fetal fraction. C, For
the single discordant fetal sex case that had a fetal fraction of 10%, SNP data clearly indicate the presence of a single maternal X-chromosome, with no
paternal X-chromosome or Y-chromosome detected, leading to the monosomy X result. Mosaicism, which is frequently seen in association with a 45,X
cell line, is a possible explanation for this discordant result.
NIPT, noninvasive prenatal testing.
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SUPPLEMENTARY TABLE 1
Prevalence of International Classification of Diseases, Ninth Revision codes in low-risk, high-risk, and advanced
maternal age women
ICD-9 code Description LR, n AMA, n HR, n Code type
228.1 Lymphangioma, any site 1 0 2 LR
278 Obesity, unspecified 0 1 1 LR
293.84 Anxiety disorder in conditions classified elsewhere 1 0 0 LR
300 Anxiety, dissociative and somatoform disorders
eanxiety state unspecified
0 0 11 LR
305.03 Alcohol abuse, in remission 0 0 1 LR
305.1 Tobacco use disorder (tobacco dependence) 0 0 1 LR
306 Physiological malfunction arising from mental factors
emusculoskeletal
0 0 1 LR
313.1 Disturbance of emotions specific to childhood and
adolescenceemisery and unhappiness disorder
1 0 0 LR
345 Epilepsy and recurrent seizures 0 0 1 LR
622.1 Dysplasia of cervix 6 0 0 LR
648.13 Thyroid dysfunctioneantepartum condition or
complicationenot delivered during current episode of
care
0 0 1 LR
649.13 Obesity complicating pregnancy, childbirth, or
puerperiumeantepartum condition or complication
enot delivered during current episode of care
0 1 0 LR
649.43 Epilepsy complicating pregnancy, childbirth, or
puerperium (antepartum obstetric condition, not
delivered during current episode of care)
0 1 0 LR
655.53 Suspected damage to fetus from drugs (antepartum
condition or complication)
1 2 1 LR
655.63 Suspected damage to fetus from radiation 0 1 0 LR
656.13 Other known or suspected fetal and placental problems
affecting management of mothereRhesus
isoimmunization
1 0 0 LR
695.3 Rosaceaeacne 0 0 1 LR
767.5 Facial nerve injuryefacial palsy 0 0 2 LR
780.39 Other convulsions 0 1 0 LR
790.92 Abnormal coagulation profile 0 0 1 LR
795.79 Other and unspecified nonspecific immunological
findings (raised antibody titer, raised level of
immunoglobulins)
0 0 1 LR
V13.29 Personal history of diseaseeother genital system and
obstetric disorders
0 0 1 LR
V13.63 Personal history of congenital malformations of
nervous system
1 0 0 LR
V19.5 Family history of skin condition 1 1 1 LR
V22.0 Supervision of normal first pregnancy 21 7 12 LR
V22.1 Supervision of other normal pregnancy 905 2421 2133 LR
V22.2 Pregnant state, incidental 28 8 6 LR
V23.41 Pregnancy with history of preterm labor 1 0 0 LR
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SUPPLEMENTARY TABLE 1
Prevalence of International Classification of Diseases, Ninth Revision codes in low-risk, high-risk, and advanced
maternal age women (continued)
ICD-9 code Description LR, n AMA, n HR, n Code type
V23.85 Pregnancy resulting from assisted reproductive
technology
0 1 0 LR
V26.31 Testing of female genetic disease carrier status 469 1476 1305 LR
V28.0 Encounter for antenatal screening of mother
escreening for chromosomal anomalies by
amniocentesis
0 2 1 LR
V28.1 Screening for raised alpha-fetoprotein levels in
amniotic fluid
0 0 2 LR
V28.3 Encounter for routine screening for malformation using
ultrasonics
2 0 1 LR
V28.6 Encounter for antenatal screening of mother
escreening for streptococcus B
1 0 0 LR
V72.40 Pregnancy examination or testepregnancy
unconfirmed
0 1 0 LR
V72.42 Pregnancy examination or testepositive result 0 0 1 LR
V77.2 Special screening for endocrine, nutritional, metabolic,
and immunity disordersemalnutrition
0 0 1 LR
V77.6 Special screen for cystic fibrosis 19 19 19 LR
V77.7 Special screen for other inborn errors of metabolism 13 14 14 LR
V78.2 Special screen for sickle-cell disease 13 14 14 LR
V78.3 Special screen for other hemoglobinopathies 13 14 14 LR
V82.9 Unspecified condition 1 0 0 LR
659.53 AMAefirst pregnancy 29a 556 116 AMA
659.6 Elderly multigravida (unspecified as to episode of care
or not applicable)
0 1 1 AMA
659.63 AMAenot first pregnancy 33a 1489 343 AMA
V23.82 Supervision of other HR pregnancy, elderly
primigravida
0 0 16 AMA
348 Other conditions of brain 0 0 1 HR
429.3 Cardiomegaly (cardiac: dilatation, hypertrophy,
Ventricular dilatation)
0 0 1 HR
591 Hydronephrosis 0 0 1 HR
593.89 Other specified disorders of kidney and uretereother 0 0 1 HR
606.9 Male infertility, unspecified 0 0 1 HR
628 Infertility, femaleeassociated with anovulation 0 0 2 HR
628.8 Infertility, female of unspecified origin 0 0 2 HR
629.9 Unspecified disorder of female genital organs 0 0 1 HR
640 Hemorrhage in early pregnancy, threatened abortion
(unspecified as to episode of care or not applicable)
0 0 2 HR
646.03 Other complications of pregnancy, not elsewhere
classifiedepapyraceous fetus (antepartum condition
or complication)
0 0 1 HR
646.3 Recurrent pregnancy loss (unspecified as to episode of
care or not applicable)
0 0 1 HR
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SUPPLEMENTARY TABLE 1
Prevalence of International Classification of Diseases, Ninth Revision codes in low-risk, high-risk, and advanced
maternal age women (continued)
ICD-9 code Description LR, n AMA, n HR, n Code type
646.31 Habitual aborter (for 646.3) 0 0 1 HR
646.33 Recurrent pregnancy loss (antepartum condition or
complication not delivered during current episode of
care)
0 0 4 HR
655.03 Central nervous system malformation in fetus
eantepartum condition or complication
0 0 12 HR
655.13 Chromosomal abnormality in fetus (antepartum
condition or complication)
0 0 408 HR
655.23 Hereditary disease in family possibly affecting fetus
(antepartum condition or complication)
0 0 70 HR
655.8 Other known or suspected fetal and placental problems
affecting management of mother
0 0 4 HR
655.83 Other known or suspected fetal abnormality, not
elsewhere classifiedeantepartum condition or
complication
0 0 185 HR
655.9 Known or suspected fetal abnormality affecting
management of mothereunspecified (unspecified as
to episode of care or not applicable)
0 0 1 HR
655.93 Known or suspected fetal abnormality affecting
management of mothereunspecified (antepartum
condition or complication)
0 0 8 HR
656.43 Intrauterine death (antepartum condition or
complication)
0 0 1 HR
656.53 Poor fetal growtheantepartum condition or
complication
0 0 2 HR
658.03 Oligohydramnios (antepartum condition or
complication)
0 0 2 HR
659.61 Elderly multigravida (antepartum condition or
complication)
0 0 1 HR
659.73 Abnormality in fetal heart rate or rhythm (antepartum
condition or complication)
0 0 1 HR
663.03 Umbilical cord complicationeprolapse of cord
epresentation of cord (antepartum condition or
complication)
0 0 1 HR
663.83 Other umbilical cord complicationsevelamentous
insertion of umbilical cord
0 0 4 HR
741 Spina bifida with hydrocephaluseunspecified region 0 0 1 HR
742.3 Congenital hydrocephalus 0 0 1 HR
742.4 Other specified anomalies of brain 0 0 3 HR
742.9 Unspecified anomaly of brain, spinal cord, and nervous
system
0 0 1 HR
745.1 Congenital anomaliesecomplete transposition of great
vessels
0 0 1 HR
745.4 Ventricular septal defect 0 0 1 HR
746.7 Hypoplastic left heart syndrome 0 0 1 HR
746.9 Unspecified anomaly of heartecongenital 0 0 1 HR
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SUPPLEMENTARY TABLE 1
Prevalence of International Classification of Diseases, Ninth Revision codes in low-risk, high-risk, and advanced
maternal age women (continued)
ICD-9 code Description LR, n AMA, n HR, n Code type
747.5 Absence or hypoplasia of umbilical arteryesingle
umbilical artery
0 0 3 HR
747.89 Other specified anomalies of circulatory systemeother
(aneurysm, congenital, specified site not elsewhere
classified)
0 0 1 HR
748.1 Other anomalies of nose 0 0 1 HR
753.29 Obstructive defects of renal pelvis and uretereother 0 0 6 HR
754.7 Other deformities of feetetalipes, unspecified 0 0 1 HR
755.34 Reduction deformities of lower limbelongitudinal
deficiency, femoral, complete or partial (congenital
absence of femur)
0 0 1 HR
756.17 Anomalies of spineespina bifida occulta 0 0 1 HR
758 Down syndrome 0 0 18 HR
758.2 Chromosomal anomalieseEdward syndrome 0 0 17 HR
758.5 Other condition due to autosomal anomalies (fetal
aneuploidy)
0 0 6 HR
758.9 Condition due to anomaly of unspecified chromosome 0 0 1 HR
759.7 Multiple congenital anomalies, so described 0 0 2 HR
759.9 Congenital anomaly, unspecified 0 0 1 HR
764 “Light for dates” without mention of fetal malnutrition 0 0 1 HR
793.20 Nonspecific (abnormal) findings on radiological and
other examination of body structureeother
intrathoracic organ
0 0 10 HR
793.60 Nonspecific (abnormal) findings on radiological and
other examination of body structureeabdominal area,
including retroperitoneum
0 0 1 HR
793.99 Nonspecific (abnormal) findings on radiological and
other examination of body structureeother (placental
finding by x-ray or ultrasound method, radiological
findings in skin and subcutaneous tissue)
0 0 2 HR
796.5 Abnormal/positive serum screening 0 0 548 HR
V13.69 Personal history of other (corrected) congenital
malformations
0 0 1 HR
V18.4 Family history of certain other specific conditions
eintellectual disabilities
0 0 1 HR
V18.9 Family history of certain other specific conditions
egenetic disease carrier
0 0 3 HR
V19.8 Family history of “other condition” 0 0 221 HR
V23.0 Pregnancy with history of infertility 0 0 123 HR
V23.49 Pregnancy with poor reproductive history (prior
pregnancy with aneuploidy)
0 0 19 HR
V23.5 Pregnancy with other poor reproductive history 0 0 123 HR
V23.81 Supervision of other HR pregnancy 0 0 15 HR
V23.89 Other HR pregnancy 0 0 5 HR
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SUPPLEMENTARY TABLE 1
Prevalence of International Classification of Diseases, Ninth Revision codes in low-risk, high-risk, and advanced
maternal age women (continued)
ICD-9 code Description LR, n AMA, n HR, n Code type
V23.9 Unspecified HR pregnancy 0 0 6 HR
V26.89 Other specified procreative management 0 0 2 HR
V28.8 Other specified antenatal screening 0 0 17 HR
V28.81 Encounter for fetal anatomic survey 0 0 1 HR
V28.89 Other specified antenatal screening (CVS, genomic
screening, nuchal translucency testing, proteomic
screening)
0 0 441 HR
V28.9 Unspecified antenatal screening 0 0 337 HR
All ICD-9 codes recorded in patients in this study were included in table.
AMA, advanced maternal age; CVS, chorionic villus sampling; HR, high-risk; ICD-9, International Classification of Diseases, Ninth Revision; LR, low-risk.
a A small number of women assigned AMA codes but aged <35 yeand therefore not AMAewere included in low-risk cohort (n ¼ 60).
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SUPPLEMENTARY TABLE 3
Details of samples with failed quality metrics
Exclusion category Count
Redraws accepted
Low fetal fraction 1667
Labchip QC failed 48
Contamination 42
Laboratory error 34
Unexplained bad model fit 24
Insufficient DNA 17
Uninformative single-nucleotide polymorphism pattern
of unknown origina
13
Multiple sequencing failures 9
Redraws not requested
Suspected egg donor/surrogate 60
Maternal loss of heterozygosity 38
Fetal loss of heterozygosity 12
Suspected maternal mosaicism 1
Suspected fetal mosaicism 1
QC, quality control.
a Unclear whether the uninformative single-nucleotide polymorphism pattern is maternal or fetal in origin.
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SUPPLEMENTARY TABLE 2
Exclusion categories for out-of-specification samples
Exclusion category Count
Redraws accepted
Insufficient serum/plasma 127
<9 wk of gestationa 70
Test cancelled 45
Sample collection date too old 28
Missing information 11
Sample damaged 4
Wrong tube 4
Otherb 26
Redraws not requested
Multiple gestation 8
Egg donor 1
Surrogate 1
a Redraws are accepted once patient reaches 9 wks of gestation; b Includes uncommon exclusion reasons, such as hemolyzed
blood samples and missing state-required waivers.
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